December 22, 2020
Director's Message
Thank You: A Message from Dr. Stan Gerson
As we end December, I, for one, am glad to see 2020 fade into the rear-view mirror. Almost like the Alfred Hitchcock movie (rear window), the whole year looked and felt wrong—unlike anything we have ever experienced. It threw immense challenges at us, pushed many to our limits, and tested us in ways we did not know possible.

What has kept me going is hearing from you—your resilience, your spiritual and collegial character, your excitement and search for new ideas, your ability to flexibly pivot and keep asking important questions, your pursuit of our mission and goals, and your compassion and care for patients and helping others.
Stan Gerson, MD
Interim Dean, School of Medicine
Director, Case Comprehensive Cancer Center
Director, National Center for Regenerative Medicine
Member/Center Highlights
Gmail users: to ensure you're always viewing the entire newsletter, check at the bottom of the email to see if the newsletter has been "clipped" and click "view entire message" if so.
NCI BSA approves 10 new and reissued concepts, endorses continued affiliation of Frederick National Laboratory
National Cancer Institute Logo
During the Dec 1-2 joint meeting of the National Cancer Institute's Board of Scientific Advisors (BSA) and the National Cancer Advisory Board (NCAB), the BSA voted unanimously for NCI to initiate an RFP of a 10-year recompetition contract for operations and technical support at the Frederick National Lab and approved the following new and reissued concepts. Presentations and recorded videocasts are now available.
Pounardjian receives Joan Harris Staff Recognition Award
John Pounardjian, MBA, associate director for administration of the Case Comprehensive Cancer Center, is this year’s recipient of the Joan Harris Staff Recognition Award, named in honor of Joan Harris, the former associate dean for faculty affairs to Dean Frederick Robbins in the 1960s. The award is given annually to a staff member who consistently exemplifies the very best work ethic and demeanor.

John was one of four School of Medicine employees honored with a staff award in 2020. Please join us in congratulating him on this honor.
Reminder: Case CCC administrative offices closed Dec 24 - Jan 3
The administrative offices of the Case Comprehensive Cancer Center will be closed from Thursday, December 24 through Sunday, January 3, 2021, as Case Western Reserve University is closed for Winter Recess. Our staff will be available again beginning Monday, January 4. We wish you safe and healthy holidays and look forward to serving you in the new year!
Informational Webinar: MS in Regenerative Medicine and Entrepreneurship (RGME)
The RGME is the first two-year master's level program in Ohio focused on Regenerative Medicine and Entrepreneurship. Students enrolled in the RGME program will have access to cutting-edge clinical and research facilities along with small biotechnology companies within the network of the National Center for Regenerative Medicine (NCRM).
Open roles at the Case Comprehensive Cancer Center
Join our team! The Case Comprehensive Cancer Center (Case CCC) is currently seeking qualified candidates for the following staff roles:

The Gastrointestinal (GI) Cancer Genetics Program at The Case Comprehensive Cancer Center, with affiliates University Hospitals Cleveland Medical Center and Cleveland Clinic, also invites applications for tenure track/tenured faculty positions at the level of Assistant, Associate or Full Professor.
What's Coming Up
Mark Your Calendar
Cancer Center Seminar Series
Friday, January 8, 2021, 12p via Zoom
Our Cancer Center Seminar Series is on Winter Break!

Our series will return again virtually for Spring 2021 on Friday, January 8 at 12 pm. Hannelore Heemers, PhD will present, "Alternative Treatment Strategies for Prostate Cancer" on behalf of the Case Comprehensive Cancer Center's GU Malignancies Program.

Dr. Heemers is associate staff at the Center for GU Malignancies Research, Cleveland Clinic Lerner Research Institute, and an adjunct assistant professor in the Department of Molecular Medicine at Case Western Reserve University School of Medicine. The Heemers laboratory research program focuses on generating insights into the specific molecular mechanisms by which the androgen receptor drives prostate cancer progression.
Registration Now Open: Cancer Disparities Symposium (Virtual)
March 4-5, 2021

The Case Comprehensive Cancer Center Office of Community Outreach and Engagement is pleased to present the 5th Annual Cancer Disparities Symposium, Navigating Cancer Disparities: Lessons Learned and How to Move Forward.
Registration is now open for this multi-disciplinary event for researchers, clinicians, health professionals, community outreach groups, community-based organizations, patient advocates and trainees. Keynote presentations will be delivered by renowned disparities researchers and community leaders, and a poster session highlighting academic research and community programs will provide a showcase of the depth and depth of work happening in this field.

Though the symposium is happening virtually, attendees will experience the conference using Whova, our official web-based conference app, to view presentations and ask questions in real-time, as well as network with others behind the scenes.

Abstract Deadline January 22
Multidisciplinary researchers, community agencies and organizations are invited to submit abstracts for presentation at the 5th Annual Cancer Disparities Symposium. Abstracts will be divided into two tracks: Scientific Research and Community Programs. Meritorious abstracts will be selected for pre-recorded presentations. Abstracts must be submitted electronically by 5 pm ET on Friday, January 22, 2021.
Keynote Speakers Announced
Otis W. Brawley, MD, an internationally-recognized expert in cancer prevention and control, will present the symposium's Scientific Keynote His work is focused on closing racial, economic and social disparities in prevention, detection and treatment of cancer in the United States and worldwide.

Worta McCaskill-Stevens, MD, a medical oncologist nationally known for her expertise in bringing clinical trials to the community will present the Community Keynote. Dr. McCaskill-Stevens is Chief of the Community Oncology and Prevention Trials Research Group, which houses the National Cancer Institute (NCI) Community Oncology Research Program (NCORP), a community-based clinical trials network launched in 2014.
Additional Upcoming Events
AACR Virtual Meeting: COVID-19 and Cancer
Meeting: February 3-5, 2021
Following the success of the first AACR COVID-19 and Cancer meeting in July, which attracted nearly 900 participants, the American Association for Cancer Research is inviting abstracts for a second meeting, which will explore the latest research into vaccines and treatment advances in the global fight against the pandemic, and its effects on cancer patients.
NCCN 2021 Virtual Congress™: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS)
Friday, February 12, 2021
Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic/prognostic tools, therapeutic options, and supportive care strategies. Healthcare professionals need to be educated on current and emerging scientific data to make evidence-based treatment decisions and to provide optimal care for patients with breast cancer.

The NCCN 2021 Virtual Congress™: Breast Cancer with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS) will provide expert insights on the current standard of care for patients with breast cancer and include the latest clinical research updates from the 2020 SABCS to assist clinicians in formulating breast cancer management strategies.
4th Annual International PTEN Symposium
Monday, March 15, 2021
The Genomic Medicine Institute and Center for Personalized Genetic Healthcare at Cleveland Clinic invite you to join the virtual 4th Annual International PTEN Symposium: From Patient-Centered Research to Clinical Care. They an engaging day with an emphasis on advances in the diagnosis, management and treatment of patients with PTEN Hamartoma Tumor Syndrome (PHTS).

Pier Paolo Pandolfi, MD, PhD, FRCP, senior scientist at the Renown Institute for Cancer and honorary professor of molecular biology at the University of Turin, will deliver the morning keynote address. Neil Friedman, MBChB, pediatric neurologist and director of quality, outcomes, and innovation at Barrow Neurological Institute at Phoenix Children’s Hospital, will deliver the afternoon keynote address on the neurological spectrum of PHTS. Other topics include hormone use and high-risk patients, gynecological cancer risks, updates on PTEN clinical trials, and autism. Please refer to the symposium agenda for more details about this year’s speakers and topics.
Funding Opportunities
The NSF Research Traineeship (NRT) program seeks proposals that explore ways for graduate students in research-based master's and doctoral degree programs to develop the skills, knowledge, and competencies needed to pursue a range of STEM careers. The program is dedicated to effective training of STEM graduate students in high priority interdisciplinary or convergent research areas, through a comprehensive traineeship model that is innovative, evidence-based, and aligned with changing workforce and research needs. Proposals are requested that address any interdisciplinary or convergent research theme of national priority, as noted above.

The NRT program addresses workforce development, emphasizing broad participation, and institutional capacity building needs in graduate education. The program encourages proposals that involve strategic collaborations with the private sector, non-governmental organizations (NGOs), government agencies, national laboratories, field stations, teaching and learning centers, informal science centers, and academic partners.
The Dream Project component of the Regeneron Prize application is designed to be a differentiating exercise that allows Regeneron's Selection Committee to distinguish between applicants who have excellent research records because of their mentors and those who have excellent research records because of their own scientific merits. The research that is proposed is not necessarily meant to be conducted, nor is the prize meant as a funding mechanism for research. The prize, $50,000 for each graduate and postdoctoral fellow winner, is a cash prize to the trainee, and the trainee may use the money in any way he or she wishes.

The proposal is a mechanism for evaluating a student's scientific clarity, elegance, precision and creativity. There is no need for preliminary data (although not prohibited), and there is no need for the student to feel limited by time or resources for the research proposed. "Out of the box" thinking is not only acceptable but encouraged. The proposal should describe research the applicant wishes he/she could conduct (i.e., a "dream" project), and be performable within the fundamental limitations imposed by today's technologies (e.g., don't propose cloning Albert Einstein). Finalists, who will also be awarded $5,000 each, will be invited to Regereron as the final step in selection of the Prize winners, and they should be prepared to explain and defend aspects of their proposal at that time.
BCAN logo
Deadline: January 13, 2021
ACS logo
LOI Deadline: February 1, 2021
The Bladder Cancer Advocacy Network (BCAN) is pleased to announce two 2021 Bladder Cancer Research Innovation Awards to support the work of investigators with exceptionally novel and creative projects with great potential to produce breakthroughs in our understanding of the management of bladder cancer. Two proposals will be funded for $300,000 at $150,000 per year. The proposed research may be basic, translational, clinical or epidemiological and must have direct applicability and relevance to bladder cancer. Innovation, either conceptual or technological, is essential.

The Bladder Cancer Research Innovation Awards are available to full-time, independent investigators who are affiliated with a non-profit academic, medical, or research institution within the United States or Canada. Eligible recipients include investigators who have experience in other areas of cancer or biomedical/health science research with promising ideas and approaches that can be applied to bladder cancer research. Projects that are high-risk and high-reward, as opposed to incremental in nature, are required. BCAN encourages diversity in applicants.
The American Cancer Society (ACS) offers a limited number of grants to investigators who have had the rank of full professor for 15 years or less and made seminal contributions that have changed the direction of basic cancer research.

It is expected that these investigators will continue to provide leadership in their research area. Up to 2 awards are made annually for a 5-year term that can be renewed once. The award of up to $80,000 per year (direct costs only) may be used for salary or research project support.

Interested individuals should submit their curriculum vitae with a complete bibliography and a letter of intent that briefly describes their seminal contributions to research. This information must be submitted via the Research Professor letter of intent on proposalCENTRAL. Upon receipt, ACS will provide appropriate guidance either by telephone or email.
In The News
SurvivorNet - November 20, 2020
A number of oral cancer diagnoses are caused by the human papillomavirus (HPV), an extremely common virus spread through sexual contact. Ted Teknos, MD explains how the HPV vaccine can prevent certain types of cancers. Dr. Teknos is Deputy Director for University Hospitals at Case Comprehensive Cancer Center.
OncLive - October 30, 2020
CAR T-cell therapy is poised to transform the treatment paradigm of relapsed/refractory multiple myeloma now that multiple products are exhibiting high and complete response (CR) rates, said Cleveland Clinic's Faiz Anwer, MD. Dr. Anwer is a member of the Hematopoietic and Immune Cancer Biology Program at Case CCC.
From The NIH
Request for Information (RFI) Regarding Opportunities for New National Programs at the National Cancer Institute’s (NCI) Frederick National Laboratory for Cancer Research
NCI has released a Request for Information (RFI) seeking input from the cancer research community on the most important needs and promising opportunities in cancer research that are difficult to address on an individual scale but could be tackled through the NCI Frederick National Laboratory for Cancer Research. This is part of a planning effort to identify unique, large-scale programs of national significance that the FNLCR could support in the interest of the entire cancer research community.

Email responses to and place "RFI Response" in the subject line. Responses will be accepted through January 18, 2021.
Weekly NIH Funding Opportunities and Notices
COVID-19 Funding Opportunities and Notices
Have something to share?
Use the button below to submit all your news, publications, events, announcements, lab openings and communications requests to the Case CCC Marketing and Communications team! We are here to help.